Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sanquin Ip B V currently faces 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners and are situated within 2 distinct art units. This indicates that the company's current filings are diverse enough to require review from multiple specialized groups at the patent office.
The busiest examiner for the portfolio is SZPERKA, MICHAEL EDWARD, who is assigned 1 pending office action. Since there are 2 pending office actions in total, the workload is divided between the 2 distinct examiners. The presence of 2 distinct art units suggests that the underlying technologies are distinct from one another. Practitioners should look for consistency in the company's overall strategy while addressing the specific requirements of each examiner and art unit.
Because the busiest examiner, SZPERKA, MICHAEL EDWARD, handles 1 pending office action, no single official dominates the prosecution of the Biotechnology & Pharmaceuticals portfolio. The use of 2 distinct examiners across 2 distinct art units requires a coordinated approach to ensure that arguments made in one case do not conflict with those in another. This distribution provides multiple points of contact with the patent office, reducing the impact of any single examiner's specific tendencies.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256750 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | WELLS, LAUREN QUINLAN | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256750 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | WELLS, LAUREN QUINLAN | 2d overdue |
| 18487297 | FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18487297 | FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18256750 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | WELLS, LAUREN QUINLAN | 1622 | §103§112 | Final Rejection | 2d overdue | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial